Callio Therapeutics Funding: $187M Raised, Series A (2025)
Callio Therapeutics is a Biotech company based in Seattle. It has raised $187M in total funding. Latest round: Series A.
Callio Therapeutics funding overview
Callio Therapeutics is a Biotech company based in Seattle. Callio Therapeutics has raised $187M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series A announced in March 2025. The round record for Callio Therapeutics runs through 2025; nothing later has been disclosed. Investors on record include Frazier Life Sciences, Jeito Capital, Novo Holdings A/S, Omega Funds, ClavystBio, Platanus and 4 others. 10 distinct backers are named across the disclosed rounds.
Callio Therapeutics at a glance
Total raised
$187M
Latest round
Series A
Latest round date
March 2025
Industry
Biotech
Headquarters
Seattle
Notable investors
Frazier Life Sciences, Jeito Capital, Novo Holdings A/S, Omega Funds, ClavystBio, Platanus, Norwest, Pureos Bioventures
Frequently asked about Callio Therapeutics funding
How much has Callio Therapeutics raised?
Callio Therapeutics has raised $187M in total disclosed funding across the rounds on record.
Who has invested in Callio Therapeutics?
Frazier Life Sciences, Jeito Capital, Novo Holdings A/S, Omega Funds, ClavystBio, Platanus are named among the investors backing Callio Therapeutics.
What was the latest Callio Therapeutics funding round?
The most recent disclosed round is a Series A, announced in March 2025.
Where is Callio Therapeutics based?
Callio Therapeutics is based in Seattle.
What sector does Callio Therapeutics operate in?
Callio Therapeutics is tracked under Biotech from Seattle, with $187M in disclosed funding.
When did Callio Therapeutics last raise?
The last disclosed Callio Therapeutics round closed in March 2025 at Series A.
Totals shown for Callio Therapeutics aggregate every disclosed round on file. To see how that compares, browse the Biotech companies in Seattle and the investors behind them below.
